End Stage Renal Disease Market Forecast 2032: Clinical Trials, FDA Approvals, Therapies, Epidemiology, and Companies by DelveInsight | Merck Sharp & Dohme, Gilead Sciences, Aronora, Amgen, Rockwell Medical Technologies

(Albany, USA) DelveInsight's "End Stage Renal Disease Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the End Stage Renal Disease, historical and forecasted epidemiology as well as the End Stage Renal Disease market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the End Stage Renal Disease market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; End Stage Renal Disease Market Forecast
https://www.delveinsight.com/sample-request/end-stage-renal-disease-esrd-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Some of the key facts of the End Stage Renal Disease Market Report:
• The End Stage Renal Disease market size is anticipated to grow with a significant CAGR during the study period (2019-2032)
• In April 2022, Fresenius Medical Care disclosed that the FDA in the United States has given approval for the Versi PD Cycler System. This is an advanced portable automated peritoneal dialysis system now authorized for use in North America.
• In March 2022, The Health Minister inaugurated a Hemodialysis unit at New Souillac in the presence of the World Health Representative to commemorate World Kidney Day in Mauritius. This new facility incorporates 22 hemodialysis machines with a capacity to serve approximately 150 patients, intending to enhance the decentralization of treatment for individuals affected by kidney disease.
• The European Renal Association - European Dialysis and Transplant Association (ERA-EDTA) Registry gathered information on Renal Replacement Therapy (RRT) for End-Stage Renal Disease (ESRD) by compiling data from national and regional renal registries in Europe and neighboring countries around the Mediterranean Sea.
• Gender variations have been observed within the nephrology domain, indicating that women exhibit a certain degree of protection against developing End-Stage Renal Disease (ESRD). The overall occurrence of ESRD remains relatively low during the reproductive years, with an onset occurring approximately a decade later in women compared to men.
• As of December 31, 2018, approximately 0.7 million individuals (785,883) were undergoing treatment for End-Stage Renal Disease (ESRD) in the United States, resulting in a point prevalence of 2,382 cases per million population. Among these, the prevalence of dialysis treatment was 1,685 per million, while the prevalence of a functioning kidney transplant was 696 per million, according to the Centers for Disease Control and Prevention (2022).
• TRIFERIC is the initial and sole FDA-approved therapy designed for the replenishment of iron to sustain hemoglobin levels in adult individuals with hemodialysis-dependent chronic kidney disease (HDD-CKD).
• Key End Stage Renal Disease Companies: Rockwell Medical Technologies, Aronora, Merck Sharp & Dohme, Gilead Sciences, Amgen, Abbott, Astellas Pharma, Veloxis Pharmaceuticals, and others
• Key End Stage Renal Disease Therapies: TRIFERIC, AB002, MK-2060, Zepatier, Epclusa, Aranesp®, Erythrocyte Stimulating Agent (ESA), paricalcitol capsules, Astagraf XL, Tacrolimus, and others
• The End Stage Renal Disease epidemiology based on gender analyzed that it can be concluded that ESRD is more common in males than females.
• The End Stage Renal Disease market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage End Stage Renal Disease pipeline products will significantly revolutionize the End Stage Renal Disease market dynamics.

End Stage Renal Disease Overview
End-stage renal disease (ESRD) is the final stage of chronic kidney disease (CKD), where the kidneys lose nearly all their ability to function effectively. This condition leads to the accumulation of waste products and fluids in the body, necessitating renal replacement therapy such as dialysis or a kidney transplant for survival. Common causes of End Stage Renal Disease include diabetes, hypertension, glomerulonephritis, and polycystic kidney disease.
Symptoms of End Stage Renal Disease are severe and can include fatigue, confusion, swelling in the extremities, shortness of breath, nausea, and a decreased appetite. These symptoms result from the buildup of toxins and excess fluid, as well as electrolyte imbalances. Additionally, ESRD can lead to complications such as cardiovascular disease, anemia, bone disease, and metabolic acidosis.
Diagnosis of End Stage Renal Disease involves blood tests showing elevated levels of waste products like creatinine and urea, along with imaging studies and urine tests to assess kidney function and structure. Management of End Stage Renal Disease focuses on replacing kidney function and managing associated symptoms and complications. Hemodialysis, peritoneal dialysis, and kidney transplantation are the primary treatments.
Preventive measures, early detection, and effective management of underlying conditions are crucial to delaying the progression of CKD to End Stage Renal Disease. Advances in treatment options and supportive care have improved the quality of life and outcomes for many patients with End Stage Renal Disease.

Get a Free sample for the End Stage Renal Disease Market Forecast, Size & Share Analysis Report:
https://www.delveinsight.com/report-store/end-stage-renal-disease-esrd-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

End Stage Renal Disease Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

End Stage Renal Disease Epidemiology Segmentation:
The End Stage Renal Disease market report proffers epidemiological analysis for the study period 2019-2032 in the 7MM segmented into:
• Total Prevalence of End Stage Renal Disease
• Prevalent Cases of End Stage Renal Disease by severity
• Gender-specific Prevalence of End Stage Renal Disease
• Diagnosed Cases of Episodic and Chronic End Stage Renal Disease

Download the report to understand which factors are driving End Stage Renal Disease epidemiology trends @ End Stage Renal Disease Epidemiology Forecast
https://www.delveinsight.com/sample-request/end-stage-renal-disease-esrd-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

End Stage Renal Disease Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the End Stage Renal Disease market or expected to get launched during the study period. The analysis covers End Stage Renal Disease market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the End Stage Renal Disease Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

End Stage Renal Disease Therapies and Key Companies
• TRIFERIC: Rockwell Medical Technologies
• AB002: Aronora
• MK-2060: Merck Sharp & Dohme
• Zepatier: Merck Sharp & Dohme
• Epclusa: Gilead Sciences
• Aranesp®: Amgen
• Erythrocyte Stimulating Agent (ESA): Rockwell Medical Technologies
• paricalcitol capsules: Abbott
• Astagraf XL: Astellas Pharma
• Tacrolimus: Veloxis Pharmaceuticals

Discover more about therapies set to grab major End Stage Renal Disease market share @ End Stage Renal Disease Treatment Landscape
https://www.delveinsight.com/sample-request/end-stage-renal-disease-esrd-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Scope of the End Stage Renal Disease Market Report
• Study Period: 2019-2032
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key End Stage Renal Disease Companies: Rockwell Medical Technologies, Aronora, Merck Sharp & Dohme, Gilead Sciences, Amgen, Abbott, Astellas Pharma, Veloxis Pharmaceuticals, and others
• Key End Stage Renal Disease Therapies: TRIFERIC, AB002, MK-2060, Zepatier, Epclusa, Aranesp®, Erythrocyte Stimulating Agent (ESA), paricalcitol capsules, Astagraf XL, Tacrolimus, and others
• End Stage Renal Disease Therapeutic Assessment: End Stage Renal Disease current marketed and End Stage Renal Disease emerging therapies
• End Stage Renal Disease Market Dynamics: End Stage Renal Disease market drivers and End Stage Renal Disease market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• End Stage Renal Disease Unmet Needs, KOL's views, Analyst's views, End Stage Renal Disease Market Access and Reimbursement

To know more about End Stage Renal Disease companies working in the treatment market, visit @ End Stage Renal Disease Clinical Trials and Therapeutic Assessment
https://www.delveinsight.com/sample-request/end-stage-renal-disease-esrd-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Table of Contents
1. End Stage Renal Disease Market Report Introduction
2. Executive Summary for End Stage Renal Disease
3. SWOT analysis of End Stage Renal Disease
4. End Stage Renal Disease Patient Share (%) Overview at a Glance
5. End Stage Renal Disease Market Overview at a Glance
6. End Stage Renal Disease Disease Background and Overview
7. End Stage Renal Disease Epidemiology and Patient Population
8. Country-Specific Patient Population of End Stage Renal Disease
9. End Stage Renal Disease Current Treatment and Medical Practices
10. End Stage Renal Disease Unmet Needs
11. End Stage Renal Disease Emerging Therapies
12. End Stage Renal Disease Market Outlook
13. Country-Wise End Stage Renal Disease Market Analysis (2019-2032)
14. End Stage Renal Disease Market Access and Reimbursement of Therapies
15. End Stage Renal Disease Market Drivers
16. End Stage Renal Disease Market Barriers
17. End Stage Renal Disease Appendix
18. End Stage Renal Disease Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

Trending Reports:
• Biochips Market: https://www.delveinsight.com/report-store/biochips-market
• Bone Anchored Hearing Systems Market: https://www.delveinsight.com/report-store/bone-anchored-hearing-systems-market
• Minimal Residual Disease Market: https://www.delveinsight.com/report-store/minimal-residual-disease-market
• Capnography Device Market: https://www.delveinsight.com/report-store/capnography-devices-market
• Pain Management Devices Market: https://www.delveinsight.com/report-store/pain-management-devices-market
• Pressure Ulcers Market Size: https://www.delveinsight.com/report-store/pressure-ulcers-market
• Blood Glucose Monitoring Systems Market: https://www.delveinsight.com/report-store/blood-glucose-monitoring-systems-market
• Dysthymia Market: https://www.delveinsight.com/report-store/major-depressive-disorder-market
• Osteoarthritis Market: https://www.delveinsight.com/report-store/knee-osteoarthritis-market
• Vascular Access Devices Market: https://www.delveinsight.com/report-store/vascular-access-device-market
• Hearing Aid Devices Market: https://www.delveinsight.com/report-store/hearing-aid-devices-market
• Lymphocytopenia Market: https://www.delveinsight.com/report-store/lymphocytopenia-market
• Gaucher Disease Market: https://www.delveinsight.com/report-store/gauchers-disease-market
• Defibrillators Market: https://www.delveinsight.com/report-store/defibrillator-market
• Human Papilomavirus Market: https://www.delveinsight.com/report-store/human-papillomavirus-hpv-market
• Bradycardia Treatment Devices Market: https://www.delveinsight.com/report-store/electrophysiology-devices-market
• Asphyxia Market: https://www.delveinsight.com/report-store/asphyxia-epidemiology-forecast
• Abetalipoproteinemia Market: https://www.delveinsight.com/report-store/abetalipoproteinemia-market
• Acute Agitation And Aggression Market: https://www.delveinsight.com/report-store/acute-agitation-and-aggression-market
• Alpha-mannosidosis Market: https://www.delveinsight.com/report-store/alpha-mannosidosis-market
• Bartonellosis Market: https://www.delveinsight.com/report-store/bartonellosis-market
• Blood Gas And Electrolyte Analyzers Market: https://www.delveinsight.com/report-store/blood-gas-and-electrolyte-analyzers-market
• Cellulitis Market: https://www.delveinsight.com/report-store/cellulitis-market
• Ocular Motility Disturbance Market: https://www.delveinsight.com/report-store/ocular-motility-disturbance-market
• Vitamin A Deficiency Market: https://www.delveinsight.com/report-store/vitamin-a-deficiency-market

Contact Us:
Ankit Nigam
Manager Marketing
info@delveinsight.com
+14699457679
https://www.delveinsight.com/asco-conference-coverage

About DelveInsight
DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.

This release was published on openPR.